STOCKHOLM, Nov 3 (Reuters) - Ivytan AB, owned by private equity firm EQT and Lyftet Holding, said on Monday it was making an offer for Q-Med in a bid which valued the Swedish biotech firm at about 3.9 billion Swedish crowns ($502 million). The 39 crown per share cash bid, which would be financed by equity, shareholder loans and bank debt, represented a 24 percent premium compared to Q-Med's closing price on Friday, Ivytan said in a statement.
